title: Clinical ambiguities--ongoing questions.
abstract: Many factors need to be considered when choosing the mode of delivery of immunoglobulin (IgG) replacement therapy for a given patient with primary immunodeficiency disease (PIDD). Despite some general guidance as provided in the previous discussions, a number of ongoing questions remain. This article attempts to provide some answers and clarification for clinical situations in which the choice of intravenous IgG (IVIG) or subcutaneous IgG (SCIG) may be ambiguous.
authors.affiliation: University of Washington School of Medicine, 1900 9th Ave., C9S-7, Seattle, WA 98101-1304, USA. troy.torgerson@seattlechildrens.org
authors.forename: Troy R
authors.initials: TR
authors.lastname: Torgerson
authors.forename: Vincent R
authors.initials: VR
authors.lastname: Bonagura
authors.forename: Ralph S
authors.initials: RS
authors.lastname: Shapiro
mesh_terms: D003658:Decision Making, Computer-Assisted; D004333:Drug Administration Routes; D019983:Guideline Adherence / Q000941:ethics; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage*; D007153:Immunologic Deficiency Syndromes / Q000453:epidemiology / Q000276:immunology / Q000628:therapy*; D028701:Patient Rights / Q000941:ethics; D017410:Practice Guidelines as Topic / Q000592:standards; D010818:Practice Patterns, Physicians' / Q000941:ethics / Q000592:standards*
chemical_list: D016756:Immunoglobulins, Intravenous